GALEAS膀胱检测在NHS血尿门诊检测膀胱癌的真实世界多中心评估
该研究前瞻性纳入英国NHS七家泌尿外科2024年10月至2025年6月期间因血尿紧急转诊的患者,在膀胱镜检查前采集尿液行GALEAS膀胱检测,并与膀胱镜及病理结果比较,共964例可评估,77例(8.0%)新诊断膀胱癌,检测阴性预测值>99%,阳性预测值50%,阳性似然比11.5,阴性似然比0.09,决策曲线分析显示对所有转诊者净获益优于膀胱镜。
要点
- GALEAS膀胱检测在血尿患者中检出71/77例膀胱癌,阴性预测值>99%。
- 检测检出全部17例肌层浸润性膀胱癌和35/36例高级别膀胱癌。
- 决策曲线分析显示对所有转诊者净获益优于膀胱镜。
核心结论
- GALEAS膀胱检测是一种可在临床实施的分子尿液检测,在血尿紧急检查患者中检出膀胱癌具有高阴性预测值和有利似然比。
- 数据表明GALEAS膀胱检测现在可用于将血尿患者分流至立即或延迟膀胱镜检查。
研究设计与样本
- 前瞻性多中心真实世界评估,2024年10月至2025年6月英国NHS七家泌尿外科因血尿紧急转诊的患者。
- 膀胱镜检查前采集尿液行GALEAS膀胱检测,结果与膀胱镜及活检/经尿道膀胱肿瘤电切病理比较。
- 964例参与者有膀胱镜和GALEAS结果,包括575例可见血尿、294例非可见血尿、95例未知。
主要发现
- 964例中77例(8.0%)新诊断病理证实膀胱癌。
- 检测检出77例膀胱癌中的71例,包括全部17例肌层浸润性膀胱癌和36例高级别膀胱癌中的35例。
- 阴性预测值>99%(95%CI 98-100),阳性预测值50%(95%CI 42-58),阳性似然比11.5,阴性似然比0.09。
- 决策曲线分析显示对所有转诊者净获益优于膀胱镜。
关键数值与推荐
- GALEAS膀胱检测检测23个膀胱癌相关基因的突变。
- 阴性预测值>99%(95%CI 98-100),阳性预测值50%(95%CI 42-58)。
- 阳性似然比11.5,阴性似然比0.09。
临床怎么用
- GALEAS膀胱检测可用于血尿患者分流至立即或延迟膀胱镜检查。
- 高阴性预测值支持在低风险患者中减少或延迟侵入性膀胱镜检查。
局限性
- 观察性研究设计且时间范围有限。
- GALEAS膀胱检测阳性但膀胱镜下无可见肿瘤的参与者缺乏后续诊断信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Cystoscopy is a core component of haematuria investigations; however, it is invasive and resource intensive. GALEAS Bladder is a DNA-based diagnostic urine test that measures mutations in 23 bladder cancer (BC)-associated genes. OBJECTIVE: We aimed to assess the diagnostic performance of GALEAS Bladder in real-world patients with haematuria and its utility as a molecular triage tool in this setting. METHODS: Patients referred for urgent investigation of haematuria were prospectively enrolled across seven UK National Health Service urology departments between October 2024 and June 2025. Urine samples were collected prior to cystoscopy and analysed by GALEAS Bladder. Assay results were compared with cystoscopy and biopsy/transurethral resection of bladder tumour findings. KEY FINDINGS AND LIMITATIONS: Cystoscopic findings and GALEAS Bladder results were available for 964 participants (575 visible and 294 non-visible haematuria, 95 unknown), including 77 (8.0%) newly diagnosed with pathology-confirmed BC. The assay detected 71 of the 77 BCs, including all 17 muscle-invasive BCs and 35 of the 36 high-grade BCs, with negative predictive value >99% (95% confidence interval [CI] 98-100), positive predictive value 50% (95% CI 42-58), positive likelihood ratio (LR) 11.5, and negative LR 0.09. Decision curve analysis showed net benefit over cystoscopy for all referrals. Limitations include observational study design over a limited timeframe and absence of subsequent diagnoses for participants with positive GALEAS Bladder test results without cystoscopically visible tumour. CONCLUSIONS AND CLINICAL IMPLICATIONS: GALEAS Bladder is a clinically implementable molecular urine test that detects new cases of BC with high negative predictive value and favourable LRs in patients undergoing urgent investigation of haematuria. These data show that GALEAS Bladder can be used now to triage patients with haematuria to immediate or deferred cystoscopy.
引用
- Silcock L, Hastings RK, Clokie S, et al. Real-World Multicentre Evaluation of GALEAS Bladder for Detecting Bladder Cancer in UK NHS Haematuria Clinics. Eur Urol Oncol. 2026. PMID: 42680595. doi:10.1016/j.euo.2026.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。